Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05387837 · ClinicalTrials.gov registry record · Phase 2

Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME

A Phase 2 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, sponsored by Ashvattha Therapeutics.

Active
Registry status
Phase 2
Development phase
50
Enrollment target
16
Study locations

NCT05387837 is a Phase 2 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration that is active but no longer recruiting, run by Ashvattha Therapeutics. The registered enrollment target is 50 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 16 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05387837, a Phase 2 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, is active but no longer recruiting, sponsored by Ashvattha Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
16
Study locations

Study Summary

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME)

Conditions Studied

Diabetic Macular Edema Neovascular Age-related Macular Degeneration

Interventions

  • DRUG D-4517.2

Study Locations (16)

Texas

  • Texas Retina Associates - Arlington - Arlington
  • Austin Retina Associates - Austin
  • Medical Center Ophthalmology Associates - Northwest - San Antonio
  • Retinal Consultants of San Antonio - San Antonio
  • Strategic Clinical Research Group - Willow Park

Missouri

  • Springield Clinic - Springfield
  • The Retina Institute - Clayton Office - St Louis

California

  • Macro Trials - Los Angeles

Illinois

  • University Retina - Lemont - Lemont

Indiana

  • Midwest Eye Institute - North - Indianapolis

Maryland

  • Cumberland Valley Retina Consultants - Hagerstown

Massachusetts

  • Ophthalmic Consultants of Boston - Boston

New Jersey

  • Envision Ocular, LLC - Bloomfield

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2022-08-31
Est. Completion 2025-09-30
Phase Phase 2

Sponsor

Ashvattha Therapeutics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05387837

The ClinicalTrials.gov registry entry for NCT05387837 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The listed sponsor is Ashvattha Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which D-4517.2 is the first listed.

NCT05387837 reports 16 study locations spanning 11 distinct geographic areas - top geographies include Texas, Missouri, California.

Frequently Asked Questions

What is clinical trial NCT05387837 about?

NCT05387837 is a clinical study titled "Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME". A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME)

What is the current status of trial NCT05387837?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2022-08-31. Estimated completion is 2025-09-30.

What conditions does trial NCT05387837 study?

This clinical trial studies the following conditions: Diabetic Macular Edema, Neovascular Age-related Macular Degeneration.

What interventions are being tested in trial NCT05387837?

The interventions under investigation include: D-4517.2 (DRUG).

Who is sponsoring clinical trial NCT05387837?

This trial is sponsored by Ashvattha Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05387837 being conducted?

This trial has 16 study locations across California, Illinois, Indiana, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetic Macular Edema

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetic Macular Edema

All registered trials for this condition

Neovascular Age-related Macular Degeneration

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.